Published on
The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
Published on
As a research trainee in infectious diseases, Dr. Molnar studies metabolic regulators to develop promising antimalarial therapies. Follow a day in her life.
Published on
A Q&A with Tami Benton, MD, who has led the Department of Child and Adolescent Psychiatry and Behavioral Sciences since 2010.
Published on
CHOP’s Culinary Medicine program develops recipes that can help ease physical symptoms or otherwise improve children’s health.
Published on
The innovative Food as Medicine program bring food and nutrition education to families facing food instability.
Published on
In 2016, our 8-year-old son Justin was airlifted to CHOP for emergency brain surgery. It hit us out of nowhere. When his sister and brother visited, Child Life came in with things like Legos and Play-Doh to distract them from his scary head wrap and get them to just play together. It took the fear out of the room.
Published on
The Hess family nearly lost their daughter to a deadly virus. Since then, they’ve given back by partnering with CHOP to help foster kids.
Published on
Children’s Hospital of Philadelphia (CHOP) has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma. This three-year gift, named The Connor Initiative: Precision Therapeutics for Osteosarcoma & Rare Cancers, will support cutting-edge research in osteosarcoma and other rare cancers.
Published on
CHOP’s HI Center, a Frontier Program, continues to set the standard for caring for children with congenital hyperinsulinism.
